• Axcella Health Inc (NASDAQ: AXLA) announced organizational and program updates, including a reprioritization of its programs for Long COVID Fatigue and Nonalcoholic Steatohepatitis (NASH) and a restructuring of operations.
• Axcella's Phase 2a trial results demonstrate the potential of AXA1125 for Long COVID fatigue. 
• Subjects who received AXA1125 had improvements in mental and physical fatigue measures that were statistically significant and clinically relevant compared to those who received a placebo. 
• The company is engaged in ongoing and productive reviews with regulators in the U.S. and Europe, and the company is aiming to advance its Long COVID Fatigue program into a potential registration trial.
• Axcella will discontinue its ongoing Phase 2b trial of AXA1125 in NASH while keeping the option to revisit this program should resource availability change. 
• Related: Axcella Shares Jump Despite Mixed Bag Data From Mid-Stage NASH Trial.
• Axcella is reducing its workforce by 85%. Among the departing employees are Bob Crane, Chief Financial Officer, and Virginia Dean, Chief People Officer.
• Axcella reached an agreement with SLR Investment Corp. (f/k/a Solar Capital Ltd) to pay down the debt obligations of the previous agreement.
• The company has initiated a process to explore a range of strategic alternatives. It works with an investment bank as a strategic advisor for this process. 
• Price Action: AXLA shares closed at $0.89 on Wednesday.

See more from Benzinga

• Lockheed Martin, Boeing Among US Defense Companies In Potential Talks For Military Gear For Vietnam
• Five Banks Including JPMorgan, Citi Invest In Risk Management Provider
• Elon Musk Says Taking Legal Action Against Jet Tracker After Son X's Car Intercepted By 'Crazy Stalker'

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.